Optimising primary molecular profiling in non-small cell lung cancer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0290939 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von R D Schouten und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp and Dohme, AstraZeneca, Novartis.
Abstract (Originalsprache)
Introduction
Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular profiling in the current standard-of-care (SoC) in a prospective observational study in the Netherlands and measured the effect of providing standardised diagnostic procedures. We also explored the potential of plasma-based molecular profiling in the primary diagnostic setting.
Methods
This multi-centre prospective study was designed to explore the performance of current clinical practice during the run-in phase using local SoC tissue profiling procedures. The subsequent phase was designed to investigate the extent to which comprehensive molecular profiling (CMP) can be maximized by protocolising tumour profiling. Successful molecular profiling was defined as completion of at least EGFR and ALK testing. Additionally, PD-L1 tumour proportions scores were explored. Lastly, the additional value of centralised plasma-based testing for EGFR and KRAS mutations using droplet digital PCR was evaluated.
Results
Total accrual was 878 patients, 22.0% had squamous cell carcinoma and 78.0% had non-squamous NSCLC. Stage I-III was seen in 54.0%, stage IV in 46.0%. Profiling of EGFR and ALK was performed in 69.9% of 136 patients included in the run-in phase, significantly more than real-world data estimates of 55% ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pulmonology, Radboud University Medical Centre, Nijmegen, The Netherlands.
- Integraal Kankercentrum Nederland (IKNL), Utrecht, The Netherlands.
- Pulmonology, Noordwest Ziekenhuis Groep, Alkmaar, The Netherlands.
- Department of Pulmonology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Pulmonology, Haaglanden Medical Centre, The Hague, The Netherlands.
ORCID-Profile: R D Schouten, M M F Schuurbiers, V van der Noort, E H F M van der Heijden, J A Burgers, B van der Maat, E Schuuring, D van den Broek, M M van den Heuvel
Förderung
- Merck Sharp and Dohme
- AstraZeneca
- Novartis
- Pfizer
- Roche
Zitieren
APA
Schouten, R. D., Schouten, I., Schuurbiers, M. M. F., van der Noort, V., Damhuis, R. A. M., van der Heijden, E. H. F. M., Burgers, J. A., Barlo, N. P., van Lindert, A. S. R., Maas, K. W., van den Brand, J. J. G., Smit, A. A. J., van Haarst, J. M. W., van der Maat, B., Schuuring, E., Blaauwgeers, H., Willems, S. M., Monkhorst, K., van den Broek, D., & van den Heuvel, M. M. (2024). Optimising primary molecular profiling in non-small cell lung cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0290939
Vancouver
Schouten RD, Schouten I, Schuurbiers MMF, van der Noort V, Damhuis RAM, van der Heijden EHFM, et al. Optimising primary molecular profiling in non-small cell lung cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0290939
BibTeX
@article{Schouten2024,
author = {Schouten, R D and Schouten, I and Schuurbiers, M M F and van der Noort, V and Damhuis, R A M and van der Heijden, E H F M and Burgers, J A and Barlo, N P and van Lindert, A S R and Maas, K W and van den Brand, J J G and Smit, A A J and van Haarst, J M W and van der Maat, B and Schuuring, E and Blaauwgeers, H and Willems, S M and Monkhorst, K and van den Broek, D and van den Heuvel, M M},
title = {Optimising primary molecular profiling in non-small cell lung cancer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0290939}
}
EUVIMED